- 門診：周一至周日全天8:00-17:00
English
English 愛爾眼科(kē)醫(yī)院集團是具(jù)有(yǒu)中(zhōng)國(guó)及全球範圍醫(yī)院規模和優質(zhì)醫(yī)療能(néng)力的眼科(kē)醫(yī)療集團，服務(wù)覆蓋亞洲、歐洲和北美洲，在中(zhōng)國(guó)内地、歐洲、東南亞擁有(yǒu)3家上市公(gōng)司(中(zhōng)國(guó)A股：愛爾眼科(kē)，300015;西班牙：CBAV;新(xīn)加坡：40T)。目前在全球範圍内開設眼科(kē)醫(yī)院及中(zhōng)心達720家，其中(zhōng)中(zhōng)國(guó)内地611家、中(zhōng)國(guó)香港7家、美國(guó)1家、歐洲89家、東南亞12家。2020年，中(zhōng)國(guó)内地年門診量超1000萬人次，手術量超100萬台，醫(yī)療服務(wù)網絡覆蓋全球近30億人口。
AIER Eye Hospital Group is a leading ophthalmic medical group (eye-care service provider) with domestic and global footprint and high-standard medical care capacity, serving patients across Asia, Europe, and North America. AIER has three public-trading companies listed in China, Europe, and Southeast Asia, respectively (Shenzhen Stock Market: AIER, 300015; Spain BME: CBAV; Singapore SGX: 40T). We have so far established 720 ophthalmic hospitals and centers across the world, including 611 hospitals and centers in mainland China, 7 in Hong Kong, China, 1 in the United States, 90 in Europe, and 12 in Southeast Asia. In 2020, we served more than 10 million outpatient visits and preformed over 1 million surgeries in mainland China. Our medical service network covers approximately 3 billion people worldwide.
愛爾眼科(kē)始終堅持以國(guó)内發展為(wèi)主線(xiàn)，國(guó)内國(guó)際雙線(xiàn)并舉，共同進步。在發展的過程中(zhōng)，緻力于引進和吸收國(guó)際同步的眼科(kē)技(jì )術與醫(yī)療管理(lǐ)理(lǐ)念，以專業化、規模化、科(kē)學(xué)化為(wèi)發展戰略，推動中(zhōng)國(guó)眼科(kē)醫(yī)療事業的發展。通過不斷實踐，在充分(fēn)吸收國(guó)際優質(zhì)的醫(yī)療管理(lǐ)經驗的基礎上，成功探索出一套适應中(zhōng)國(guó)國(guó)情和市場環境的眼科(kē)醫(yī)院連鎖經營管理(lǐ)模式——“分(fēn)級連鎖”，充分(fēn)發揮人才、技(jì )術和管理(lǐ)等方面的優勢，提升診療質(zhì)量、完善醫(yī)療服務(wù)、優化醫(yī)患溝通。
Domestic market is the core business of AIER and international market plays a more and more important role in our global strategy. We are committed to introducing and absorbing the cutting-edge technology and advanced management concepts, as well as to contributing to the evolution of China's ophthalmology market, in a specialized, scaled-up and scientific way.
AIER has successfully explored the business model in line with China’s national and market condition through continuous practice- the “hierarchical chain”- to fully utilize advantages in talent, technology and management so as to achieve better clinical outcome, to improve service standard and to optimize communication between patients and medical personnel.
科(kē)研創新(xīn)、人才培養是長(cháng)遠(yuǎn)發展的基石，愛爾眼科(kē)不斷加大科(kē)研投入，大力支持開展前沿性、原創性的眼科(kē)學(xué)術研究，全力推進全球化平台上的眼健康生态圈戰略。自2013年愛爾眼科(kē)與中(zhōng)南大學(xué)聯合成立中(zhōng)南大學(xué)愛爾眼科(kē)學(xué)院，正式開啓校企合作(zuò)的創新(xīn)探索以來，陸續推動了與湖(hú)北科(kē)技(jì )學(xué)院、武漢大學(xué)、暨南大學(xué)、安(ān)徽醫(yī)科(kē)大學(xué)、天津大學(xué)、四川大學(xué)等知名(míng)高校的戰略合作(zuò)，充分(fēn)發揮企業和高校的獨特優勢，在醫(yī)院共建、人才培養、師資隊伍建設、教學(xué)科(kē)研等領域展開深入合作(zuò)，聯手共建眼科(kē)醫(yī)教研平台，合力打造“名(míng)校+名(míng)企”典範，為(wèi)社會培養更多(duō)優秀的眼科(kē)醫(yī)學(xué)人才，真正地為(wèi)中(zhōng)國(guó)眼科(kē)學(xué)和視覺科(kē)學(xué)的創新(xīn)發展貢獻智慧與力量。
Scientific research innovation and talent cultivation are the cornerstones of long-term development. We vigorously support the development of original and cutting-edge scientific research and make ourselves committed to creating a closed-loop ophthalmic ecosystem on a global platform by gradually increasing investment.
Since the joint establishment of AIER School of Ophthalmology of Central South University by AIER and Central South University in 2013, an innovative exploration of school-enterprise cooperation was officially launched. AIER then successively promoted strategic cooperation with well-known universities, such as Hubei University of Science and Technology, Wuhan University, Jinan University, Anhui Medical University, Tianjin University, and Sichuan University, etc.
AIER and the universities are sharing the same goal to build an integrated education and research platform by leveraging the strengths of “Good Company” and “Famous University” through in-depth collaboration in areas of hospital co-management, talent and faculty training, academic development and scientific research, so as to train excellent ophthalmic talents for the community, as well as to contribute our wisdom and power to the evolution of the ophthalmology and vision science in China.
在此基礎上，愛爾眼科(kē)持續打造立體(tǐ)化科(kē)研平台，截止目前已在全國(guó)範圍内構建起“八所、二站、二基地、三中(zhōng)心”的創新(xīn)型科(kē)教研一體(tǐ)化平台。“八所”：愛爾眼科(kē)研究所、愛爾眼視光研究所、愛爾角膜病研究所、愛爾屈光研究所、愛爾視網膜研究所、愛爾青光眼研究所、愛爾白内障與人工(gōng)晶狀體(tǐ)研究所、武漢愛爾眼科(kē)研究所。獲批設立“二站”：國(guó)家博士後科(kē)研工(gōng)作(zuò)站、湖(hú)南省院士專家工(gōng)作(zuò)站；“二基地”：湖(hú)南省眼視光國(guó)際科(kē)技(jì )合作(zuò)基地、湖(hú)南省“海智計劃”工(gōng)作(zuò)基地；“三中(zhōng)心”：湖(hú)南省眼視光工(gōng)程技(jì )術研究中(zhōng)心、湖(hú)南省眼表疾病臨床醫(yī)學(xué)研究中(zhōng)心、湖(hú)南省企業技(jì )術中(zhōng)心；聯合共建“愛爾眼科(kē)-中(zhōng)科(kē)院計算所數字眼科(kē)聯合實驗室”等創新(xīn)平台。
Based on this, AIER continued to create a comprehensive scientific research platform. Up to now, an innovative platform integrating science, education and research. “Eight Institutes, Two Stations, Two Bases, and Three Centers” has been established nationwide.
“Eight Institutes” refers to Eye Institute, Optometry & Visual Science Institute, Keratoconus Institute, Refractive Institute, Retina Institute, Glaucoma Institute, Cataract Institute, and AIER Ophthalmic Research Institute in Wuhan; “Two Stations” refers to National Post-Doctorates R&D Workstation and Academician Expert Hunan Provincial Workstation, which was established after approval; “Two Bases” refers to Hunan International Optometry Science and Technology Cooperation Base and HOME Program work base in Hunan Province; “Three Centers” refers to Hunan Optometry Engineering Technology Research Center, Hunan Ocular Surface Disease Clinical Medicine Research Center, and Hunan Enterprise Technology Center; meanwhile various innovative platforms such as “AIER-ICT Digital Ophthalmology Joint Laboratory” were jointly established.
上市十年之際，愛爾眼科(kē)以“創新(xīn)驅動，科(kē)技(jì )愛爾”作(zuò)為(wèi)指導方針，提出三大戰略目标。第一個目标是要将愛爾眼科(kē)的醫(yī)療服務(wù)網絡覆蓋到廣大城鄉縣域，讓老百姓在家門口就能(néng)享受到高質(zhì)量的、可(kě)及的眼科(kē)醫(yī)療服務(wù)，助推健康中(zhōng)國(guó)戰略。第二個目标是希望通過打造世界級及國(guó)家級的眼科(kē)醫(yī)學(xué)中(zhōng)心，切實提高中(zhōng)國(guó)眼科(kē)醫(yī)療技(jì )術水平，趕超世界先進水平。第三個目标是希望通過全球化布局，醫(yī)、教、研、産(chǎn)、投全面協同發展，推動人類眼科(kē)學(xué)與視覺科(kē)學(xué)進步。
On the 10th Anniversary of listing, AIER took “Innovation Driven and Technology Empowered” as the guideline and proposed three strategic goals. The first goal is to expand the medical service network into vast urban and rural areas, enabling patients to experience convenient and high-quality ophthalmic medical service, implementing the strategy of “Healthy China”. The second goal is to continuously improve ophthalmic medical technology in China and to be recognized as world-level excellence by building up world-class and national-level ophthalmic medical center. The last but not the least goal is to promote advancement of human ophthalmology and visual science through global footprint as well as coordinated development of medicine, education, research, production and investment.
在十九年的創業發展曆程中(zhōng)，愛爾眼科(kē)凝聚和培養了一批經驗豐富、具(jù)有(yǒu)開拓創新(xīn)精(jīng)神的管理(lǐ)團隊和醫(yī)術精(jīng)良、治學(xué)嚴謹的眼科(kē)專家和醫(yī)生團隊。截至目前，愛爾眼科(kē)醫(yī)院集團及旗下全球員工(gōng)總數達50000餘人，其中(zhōng)眼科(kē)醫(yī)生及視光師總數(含海外) 9000餘人，包括一大批博士生導師、碩士生導師、博士、博士後、留學(xué)歐美的學(xué)者以及臨床經驗豐富的核心專家。
Through the past 19-year growth and expansion, AIER has attracted and cultivated a group of experienced management team with innovative spirit, as well as a team of well-trained ophthalmologists and doctors with excellent medical skills and rigorous scholarship. At present, AIER has more than 50,000 employees worldwide. Among them, 9,000 are ophthalmologists and optometrists (including domestic and overseas), with a big group of doctoral supervisors, master supervisors, doctors, post-doctors, oversea scholars, and even core experts with extensive clinical experiences.
愛爾眼科(kē)的發展壯大始終以“使所有(yǒu)人，無論貧窮富裕，都享有(yǒu)眼健康的權利”為(wèi)初心和使命，緻力于全人類的光明事業，堅持“以患者為(wèi)中(zhōng)心”，追求社會責任和自身發展的和諧統一。通過開創性的“交叉補貼”模式，在為(wèi)患者提供更高品質(zhì)的眼科(kē)醫(yī)療服務(wù)的同時，全面開展防盲治盲工(gōng)作(zuò)、投身社會公(gōng)益、幫助弱勢群體(tǐ)，積極聯合社會各界力量，推動中(zhōng)國(guó)防盲事業乃至國(guó)民(mín)眼健康事業的全面發展。2018年、2020年蟬聯第十屆、第十一屆中(zhōng)國(guó)政府榮譽慈善獎項“中(zhōng)華慈善獎”、榮獲中(zhōng)國(guó)公(gōng)益年會“中(zhōng)國(guó)公(gōng)益企業獎”、“最佳社會責任上市公(gōng)司”、“湖(hú)南慈善獎”等榮譽。同時積極響應國(guó)家号召，作(zuò)為(wèi)中(zhōng)國(guó)代表企業牽頭參與“一帶一路光明行”、“湄公(gōng)河光明行”等公(gōng)益活動，獲得組織者、受援國(guó)政府和患者的高度好評，逐步發展成為(wèi)全球慈善公(gōng)益活動的一張名(míng)片。
The growth of AIER always sticks to the original intention and mission of “Enabling everyone, no matter rich or poor, has the right to eye health”. We are committed to the bright future of all human beings, insisting on “patient-oriented” principle, and pursuing the harmonious unity of social responsibility and self-development. By adopting the pioneering “Cross Subsidy Model”, while offering our patients higher-quality ophthalmic medical service, AIER also comprehensively carries out blindness prevention and treatment, devotes to public welfare, helps vulnerable groups, and actively unites all forces from society, promoting the comprehensive development of China’s blindness prevention and even the eye health career of citizens. In 2018 and 2020, AIER was awarded the 10th and the 11th “China Charity Award” by Chinese Government. Besides, we were also awarded many other honors, such as “China Public Welfare Enterprise Award”, “Best Socially Responsible Public Company”, and “Hunan Charity Award”, etc. Moreover, AIER responded positively to the national appeal and took the lead in different public benefit activities such as “The Belt and Road Brightness Campaign” and “Mekong Brightness Campaign”, winning unanimous praise from organizers, aid recipient governments and patients. In this way, AIER has been gradually regarded as a representative of global philanthropy activities.
愛爾眼科(kē)連續多(duō)年被權威機構評為(wèi)“中(zhōng)國(guó)最受投資者尊重的上市公(gōng)司前十強”，蟬聯中(zhōng)國(guó)品牌節“華譜獎”，榮獲“最佳持續投資價值獎”、“中(zhōng)國(guó)上市公(gōng)司最佳股東回報獎”、“中(zhōng)國(guó)上市公(gōng)司實業貢獻大獎”等多(duō)項殊榮，成功入選滬深300指數股、MSCI中(zhōng)國(guó)大盤指數成份股等。
AIER has been rated as “Top 10 Most Valued Public Company in China” by authoritative institutions for multiple consecutive years. We won the “China Spectrum Award” of China Brand Festival consecutively and many other honors, including “Best Sustainable Investment Value Award”, “Chinese Public Company Best Shareholder Return Award”, and “Chinese Public Company Industrial Contribution Award”, etc. At the same time, AIER was also successfully selected as CSI 300 Index Stock and MSCI China Index Constituent Stock, etc.
愛爾眼科(kē)醫(yī)院集團是具(jù)有(yǒu)中(zhōng)國(guó)及全球範圍醫(yī)院規模和優質(zhì)醫(yī)療能(néng)力的眼科(kē)醫(yī)療集團，服務(wù)覆蓋亞洲、歐洲和北美洲，在中(zhōng)國(guó)内地、歐洲、東南亞擁有(yǒu)3家上市公(gōng)司(中(zhōng)國(guó)A股：愛爾眼科(kē)，300015;西班牙：CBAV;新(xīn)加坡：40T)。目前在全球範圍内開設眼科(kē)醫(yī)院及中(zhōng)心達720家，其中(zhōng)中(zhōng)國(guó)内地611家、中(zhōng)國(guó)香港7家、美國(guó)1家、歐洲89家、東南亞12家。2020年，中(zhōng)國(guó)内地年門診量超1000萬人次，手術量超100萬台，醫(yī)療服務(wù)網絡覆蓋全球近30億人口。
AIER Eye Hospital Group is a leading ophthalmic medical group (eye-care service provider) with domestic and global footprint and high-standard medical care capacity, serving patients across Asia, Europe, and North America. AIER has three public-trading companies listed in China, Europe, and Southeast Asia, respectively (Shenzhen Stock Market: AIER, 300015; Spain BME: CBAV; Singapore SGX: 40T). We have so far established 720 ophthalmic hospitals and centers across the world, including 611 hospitals and centers in mainland China, 7 in Hong Kong, China, 1 in the United States, 90 in Europe, and 12 in Southeast Asia. In 2020, we served more than 10 million outpatient visits and preformed over 1 million surgeries in mainland China. Our medical service network covers approximately 3 billion people worldwide.
愛爾眼科(kē)始終堅持以國(guó)内發展為(wèi)主線(xiàn)，國(guó)内國(guó)際雙線(xiàn)并舉，共同進步。在發展的過程中(zhōng)，緻力于引進和吸收國(guó)際同步的眼科(kē)技(jì )術與醫(yī)療管理(lǐ)理(lǐ)念，以專業化、規模化、科(kē)學(xué)化為(wèi)發展戰略，推動中(zhōng)國(guó)眼科(kē)醫(yī)療事業的發展。通過不斷實踐，在充分(fēn)吸收國(guó)際優質(zhì)的醫(yī)療管理(lǐ)經驗的基礎上，成功探索出一套适應中(zhōng)國(guó)國(guó)情和市場環境的眼科(kē)醫(yī)院連鎖經營管理(lǐ)模式——“分(fēn)級連鎖”，充分(fēn)發揮人才、技(jì )術和管理(lǐ)等方面的優勢，提升診療質(zhì)量、完善醫(yī)療服務(wù)、優化醫(yī)患溝通。
Domestic market is the core business of AIER and international market plays a more and more important role in our global strategy. We are committed to introducing and absorbing the cutting-edge technology and advanced management concepts, as well as to contributing to the evolution of China's ophthalmology market, in a specialized, scaled-up and scientific way.
AIER has successfully explored the business model in line with China’s national and market condition through continuous practice- the “hierarchical chain”- to fully utilize advantages in talent, technology and management so as to achieve better clinical outcome, to improve service standard and to optimize communication between patients and medical personnel.
科(kē)研創新(xīn)、人才培養是長(cháng)遠(yuǎn)發展的基石，愛爾眼科(kē)不斷加大科(kē)研投入，大力支持開展前沿性、原創性的眼科(kē)學(xué)術研究，全力推進全球化平台上的眼健康生态圈戰略。自2013年愛爾眼科(kē)與中(zhōng)南大學(xué)聯合成立中(zhōng)南大學(xué)愛爾眼科(kē)學(xué)院，正式開啓校企合作(zuò)的創新(xīn)探索以來，陸續推動了與湖(hú)北科(kē)技(jì )學(xué)院、武漢大學(xué)、暨南大學(xué)、安(ān)徽醫(yī)科(kē)大學(xué)、天津大學(xué)、四川大學(xué)等知名(míng)高校的戰略合作(zuò)，充分(fēn)發揮企業和高校的獨特優勢，在醫(yī)院共建、人才培養、師資隊伍建設、教學(xué)科(kē)研等領域展開深入合作(zuò)，聯手共建眼科(kē)醫(yī)教研平台，合力打造“名(míng)校+名(míng)企”典範，為(wèi)社會培養更多(duō)優秀的眼科(kē)醫(yī)學(xué)人才，真正地為(wèi)中(zhōng)國(guó)眼科(kē)學(xué)和視覺科(kē)學(xué)的創新(xīn)發展貢獻智慧與力量。
Scientific research innovation and talent cultivation are the cornerstones of long-term development. We vigorously support the development of original and cutting-edge scientific research and make ourselves committed to creating a closed-loop ophthalmic ecosystem on a global platform by gradually increasing investment.
Since the joint establishment of AIER School of Ophthalmology of Central South University by AIER and Central South University in 2013, an innovative exploration of school-enterprise cooperation was officially launched. AIER then successively promoted strategic cooperation with well-known universities, such as Hubei University of Science and Technology, Wuhan University, Jinan University, Anhui Medical University, Tianjin University, and Sichuan University, etc.
AIER and the universities are sharing the same goal to build an integrated education and research platform by leveraging the strengths of “Good Company” and “Famous University” through in-depth collaboration in areas of hospital co-management, talent and faculty training, academic development and scientific research, so as to train excellent ophthalmic talents for the community, as well as to contribute our wisdom and power to the evolution of the ophthalmology and vision science in China.
在此基礎上，愛爾眼科(kē)持續打造立體(tǐ)化科(kē)研平台，截止目前已在全國(guó)範圍内構建起“八所、二站、二基地、三中(zhōng)心”的創新(xīn)型科(kē)教研一體(tǐ)化平台。“八所”：愛爾眼科(kē)研究所、愛爾眼視光研究所、愛爾角膜病研究所、愛爾屈光研究所、愛爾視網膜研究所、愛爾青光眼研究所、愛爾白内障與人工(gōng)晶狀體(tǐ)研究所、武漢愛爾眼科(kē)研究所。獲批設立“二站”：國(guó)家博士後科(kē)研工(gōng)作(zuò)站、湖(hú)南省院士專家工(gōng)作(zuò)站；“二基地”：湖(hú)南省眼視光國(guó)際科(kē)技(jì )合作(zuò)基地、湖(hú)南省“海智計劃”工(gōng)作(zuò)基地；“三中(zhōng)心”：湖(hú)南省眼視光工(gōng)程技(jì )術研究中(zhōng)心、湖(hú)南省眼表疾病臨床醫(yī)學(xué)研究中(zhōng)心、湖(hú)南省企業技(jì )術中(zhōng)心；聯合共建“愛爾眼科(kē)-中(zhōng)科(kē)院計算所數字眼科(kē)聯合實驗室”等創新(xīn)平台。
Based on this, AIER continued to create a comprehensive scientific research platform. Up to now, an innovative platform integrating science, education and research. “Eight Institutes, Two Stations, Two Bases, and Three Centers” has been established nationwide.
“Eight Institutes” refers to Eye Institute, Optometry & Visual Science Institute, Keratoconus Institute, Refractive Institute, Retina Institute, Glaucoma Institute, Cataract Institute, and AIER Ophthalmic Research Institute in Wuhan; “Two Stations” refers to National Post-Doctorates R&D Workstation and Academician Expert Hunan Provincial Workstation, which was established after approval; “Two Bases” refers to Hunan International Optometry Science and Technology Cooperation Base and HOME Program work base in Hunan Province; “Three Centers” refers to Hunan Optometry Engineering Technology Research Center, Hunan Ocular Surface Disease Clinical Medicine Research Center, and Hunan Enterprise Technology Center; meanwhile various innovative platforms such as “AIER-ICT Digital Ophthalmology Joint Laboratory” were jointly established.
上市十年之際，愛爾眼科(kē)以“創新(xīn)驅動，科(kē)技(jì )愛爾”作(zuò)為(wèi)指導方針，提出三大戰略目标。第一個目标是要将愛爾眼科(kē)的醫(yī)療服務(wù)網絡覆蓋到廣大城鄉縣域，讓老百姓在家門口就能(néng)享受到高質(zhì)量的、可(kě)及的眼科(kē)醫(yī)療服務(wù)，助推健康中(zhōng)國(guó)戰略。第二個目标是希望通過打造世界級及國(guó)家級的眼科(kē)醫(yī)學(xué)中(zhōng)心，切實提高中(zhōng)國(guó)眼科(kē)醫(yī)療技(jì )術水平，趕超世界先進水平。第三個目标是希望通過全球化布局，醫(yī)、教、研、産(chǎn)、投全面協同發展，推動人類眼科(kē)學(xué)與視覺科(kē)學(xué)進步。
On the 10th Anniversary of listing, AIER took “Innovation Driven and Technology Empowered” as the guideline and proposed three strategic goals. The first goal is to expand the medical service network into vast urban and rural areas, enabling patients to experience convenient and high-quality ophthalmic medical service, implementing the strategy of “Healthy China”. The second goal is to continuously improve ophthalmic medical technology in China and to be recognized as world-level excellence by building up world-class and national-level ophthalmic medical center. The last but not the least goal is to promote advancement of human ophthalmology and visual science through global footprint as well as coordinated development of medicine, education, research, production and investment.
在十九年的創業發展曆程中(zhōng)，愛爾眼科(kē)凝聚和培養了一批經驗豐富、具(jù)有(yǒu)開拓創新(xīn)精(jīng)神的管理(lǐ)團隊和醫(yī)術精(jīng)良、治學(xué)嚴謹的眼科(kē)專家和醫(yī)生團隊。截至目前，愛爾眼科(kē)醫(yī)院集團及旗下全球員工(gōng)總數達50000餘人，其中(zhōng)眼科(kē)醫(yī)生及視光師總數(含海外) 9000餘人，包括一大批博士生導師、碩士生導師、博士、博士後、留學(xué)歐美的學(xué)者以及臨床經驗豐富的核心專家。
Through the past 19-year growth and expansion, AIER has attracted and cultivated a group of experienced management team with innovative spirit, as well as a team of well-trained ophthalmologists and doctors with excellent medical skills and rigorous scholarship. At present, AIER has more than 50,000 employees worldwide. Among them, 9,000 are ophthalmologists and optometrists (including domestic and overseas), with a big group of doctoral supervisors, master supervisors, doctors, post-doctors, oversea scholars, and even core experts with extensive clinical experiences.
愛爾眼科(kē)的發展壯大始終以“使所有(yǒu)人，無論貧窮富裕，都享有(yǒu)眼健康的權利”為(wèi)初心和使命，緻力于全人類的光明事業，堅持“以患者為(wèi)中(zhōng)心”，追求社會責任和自身發展的和諧統一。通過開創性的“交叉補貼”模式，在為(wèi)患者提供更高品質(zhì)的眼科(kē)醫(yī)療服務(wù)的同時，全面開展防盲治盲工(gōng)作(zuò)、投身社會公(gōng)益、幫助弱勢群體(tǐ)，積極聯合社會各界力量，推動中(zhōng)國(guó)防盲事業乃至國(guó)民(mín)眼健康事業的全面發展。2018年、2020年蟬聯第十屆、第十一屆中(zhōng)國(guó)政府榮譽慈善獎項“中(zhōng)華慈善獎”、榮獲中(zhōng)國(guó)公(gōng)益年會“中(zhōng)國(guó)公(gōng)益企業獎”、“最佳社會責任上市公(gōng)司”、“湖(hú)南慈善獎”等榮譽。同時積極響應國(guó)家号召，作(zuò)為(wèi)中(zhōng)國(guó)代表企業牽頭參與“一帶一路光明行”、“湄公(gōng)河光明行”等公(gōng)益活動，獲得組織者、受援國(guó)政府和患者的高度好評，逐步發展成為(wèi)全球慈善公(gōng)益活動的一張名(míng)片。
The growth of AIER always sticks to the original intention and mission of “Enabling everyone, no matter rich or poor, has the right to eye health”. We are committed to the bright future of all human beings, insisting on “patient-oriented” principle, and pursuing the harmonious unity of social responsibility and self-development. By adopting the pioneering “Cross Subsidy Model”, while offering our patients higher-quality ophthalmic medical service, AIER also comprehensively carries out blindness prevention and treatment, devotes to public welfare, helps vulnerable groups, and actively unites all forces from society, promoting the comprehensive development of China’s blindness prevention and even the eye health career of citizens. In 2018 and 2020, AIER was awarded the 10th and the 11th “China Charity Award” by Chinese Government. Besides, we were also awarded many other honors, such as “China Public Welfare Enterprise Award”, “Best Socially Responsible Public Company”, and “Hunan Charity Award”, etc. Moreover, AIER responded positively to the national appeal and took the lead in different public benefit activities such as “The Belt and Road Brightness Campaign” and “Mekong Brightness Campaign”, winning unanimous praise from organizers, aid recipient governments and patients. In this way, AIER has been gradually regarded as a representative of global philanthropy activities.
愛爾眼科(kē)連續多(duō)年被權威機構評為(wèi)“中(zhōng)國(guó)最受投資者尊重的上市公(gōng)司前十強”，蟬聯中(zhōng)國(guó)品牌節“華譜獎”，榮獲“最佳持續投資價值獎”、“中(zhōng)國(guó)上市公(gōng)司最佳股東回報獎”、“中(zhōng)國(guó)上市公(gōng)司實業貢獻大獎”等多(duō)項殊榮，成功入選滬深300指數股、MSCI中(zhōng)國(guó)大盤指數成份股等。
AIER has been rated as “Top 10 Most Valued Public Company in China” by authoritative institutions for multiple consecutive years. We won the “China Spectrum Award” of China Brand Festival consecutively and many other honors, including “Best Sustainable Investment Value Award”, “Chinese Public Company Best Shareholder Return Award”, and “Chinese Public Company Industrial Contribution Award”, etc. At the same time, AIER was also successfully selected as CSI 300 Index Stock and MSCI China Index Constituent Stock, etc.
